TRIAZOLAM 0.25 MG — DIN 00808571
TRIAZOLAM : 0.25 MG · AA PHARMA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TRIAZOLAM?
TRIAZOLAM 0.25 MG contains TRIAZOLAM : 0.25 MG. It is listed in the Health Canada Drug Product Database under DIN 00808571, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Jun-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRIAZOLAM used for?
TRIAZOLAM (Triazolam Tablets USP) is indicated for the symptomatic relief of transient and short-term insomnia in patients who have difficulty falling asleep. Triazolam is not recommended for early morning awakenings. The use of hypnotics should be restricted for insomnia where disturbed sleep results in impaired daytime functioning.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Triazolam in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Triazolam, across 16 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AA PHARMA INC | 2 | 1 | TRIAZOLAM | Sourceable in Canada |
| ALTIMED PHARMA INC. | 2 | 0 | ALTI-TRIAZOLAM TAB 0.125MG, ALTI-TRIAZOLAM TAB 0.25MG | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MYLAN-TRIAZOLAM | No marketed DIN |
| NOVOPHARM LIMITED | 2 | 0 | NOVO-TRIOLAM TAB 0.125MG, NOVO-TRIOLAM TAB 0.25MG | No marketed DIN |
| PENTAPHARM LTD. | 2 | 0 | PENTA-TRIAZOLAM TABLETS | No marketed DIN |
| PFIZER CANADA ULC | 2 | 0 | HALCION | No marketed DIN |
| PREMPHARM INC | 2 | 0 | TRIAZOLAM TABLETS 0.125MG, TRIAZOLAM TABLETS 0.25MG | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | TRIAZOLAM TAB 0.125MG, TRIAZOLAM TAB 0.25MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.25 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Available in cartons containing 70 unit of use blister strips of 7 tablets each (490 tablets/carton). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Triazolam |
|---|---|
| ATC code | N05CD05 |
| AHFS class | 28:24.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00808571 |
|---|---|
| DIN (unpadded, as printed on some documents) | 808571 |
| Brand name | TRIAZOLAM |
| Generic / active ingredient | TRIAZOLAM : 0.25 MG |
| Market authorization holder | AA PHARMA INC |
| Health Canada schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05CD05 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05CD |
| Current status | MARKETED |
| Status date | 27-Jun-2014 |
| Original market date | 1989-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 16 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALTI-TRIAZOLAM TAB 0.125MG | .125 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | 00614351 |
| ALTI-TRIAZOLAM TAB 0.25MG | .25 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | 00614378 |
| HALCION | 0.25 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | 00443158 |
| HALCION | 0.125 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | 00512559 |
| MYLAN-TRIAZOLAM | 0.125 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | 01995227 |
| MYLAN-TRIAZOLAM | 0.25 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | 01913506 |
| NOVO-TRIOLAM TAB 0.125MG | .125 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | 00872423 |
| NOVO-TRIOLAM TAB 0.25MG | .25 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | 00872431 |
| PENTA-TRIAZOLAM TABLETS | .125 MG | TABLET | PENTAPHARM LTD. | CANCELLED (UNRETURNED ANNUAL) | 02232553 |
| PENTA-TRIAZOLAM TABLETS | .25 MG | TABLET | PENTAPHARM LTD. | CANCELLED (UNRETURNED ANNUAL) | 02232554 |
2 · Same class — other molecules in ATC N05CD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Midazolam | APO-MIDAZOLAM INJECTABLE 1 MG/ML · APO-MIDAZOLAM INJECTABLE 5 MG/ML · BUCCOLAM · MIDAZOLAM INJECTION · +7 more | 32 | 14 | Yes |
| Temazepam | APO-TEMAZEPAM · CO TEMAZEPAM CAPSULES 15MG · CO TEMAZEPAM CAPSULES 30MG · DOM-TEMAZEPAM · +14 more | 28 | 2 | Yes |
| Flurazepam | BIO-FLURAZEPAM · DALMANE · FLURAZEPAM · FLURAZEPAM 15 · +12 more | 20 | 2 | Yes |
| Nitrazepam | APO-NITRAZEPAM · MOGADON · NITRAZADON · NITRAZEPAM-10 · +2 more | 10 | 2 | Yes |
| Triazolam | ALTI-TRIAZOLAM TAB 0.125MG · ALTI-TRIAZOLAM TAB 0.25MG · HALCION · MYLAN-TRIAZOLAM · +8 more | 16 | 1 | Yes |
| Estazolam | PROSOM TAB 1MG · PROSOM TAB 2MG | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05CF | Eszopiclone · Zaleplon · Zolpidem · Zopiclone | 125 | 57 |
| N05CM | Dexmedetomidine · Ethchlorvynol · Scopolamine · Valerianae Radix | 31 | 11 |
| N05CC | Chloral Hydrate · Paraldehyde | 9 | 1 |
| N05CJ | Daridorexant · Suvorexant | 6 | 1 |
| N05CA | Amobarbital · Barbiturates, Plain · Pentobarbital · Secobarbital | 14 | 0 |
| N05CB | Combinations Of Barbiturates | 2 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TRIAZOLAM called?
The same molecule, Triazolam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Halcion | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Triazolam called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Triazolam, published to help those searches reach this page.
| Language | Triazolam |
|---|---|
| Arabic العربية | تريازولام |
| Chinese (Simplified) 简体中文 | 三唑仑 |
| Russian Русский | Триазолам |
| Spanish Español | Triazolam |
| French Français | Triazolam |
| Portuguese Português | Triazolam |
| German Deutsch | Triazolam |
| Japanese 日本語 | トリアゾラム |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.